Assessing prostate cancer risk

Results from the Prostate Cancer Prevention Trial

Ian M. Thompson, Donna P Ankerst, Chen Chi, Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Ziding Feng, Howard L. Parnes, Charles A. Coltman

Research output: Contribution to journalArticle

649 Citations (Scopus)

Abstract

Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. Methods: We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy. Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy. Risk equations were created from the estimated logistic regression models. All statistical tests were two-sided. Results: A total of 1211 (21.9%) men were diagnosed with prostate cancer by prostate biopsy. Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE result, whereas a previous negative prostate biopsy was associated with reduced risk. Neither age at biopsy nor PSA velocity contributed independent prognostic information. Higher PSA level, abnormal DRE result, older age at biopsy, and African American race were predictive for high-grade disease (Gleason score ≥7) whereas a previous negative prostate biopsy reduced this risk. Conclusions: This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.

Original languageEnglish (US)
Pages (from-to)529-534
Number of pages6
JournalJournal of the National Cancer Institute
Volume98
Issue number8
DOIs
StatePublished - Apr 19 2006

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Biopsy
Prostate
Digital Rectal Examination
Logistic Models
Neoplasm Grading
African Americans
Placebos

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., ... Coltman, C. A. (2006). Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 98(8), 529-534. https://doi.org/10.1093/jnci/djj131

Assessing prostate cancer risk : Results from the Prostate Cancer Prevention Trial. / Thompson, Ian M.; Ankerst, Donna P; Chi, Chen; Goodman, Phyllis J.; Tangen, Catherine M.; Lucia, M. Scott; Feng, Ziding; Parnes, Howard L.; Coltman, Charles A.

In: Journal of the National Cancer Institute, Vol. 98, No. 8, 19.04.2006, p. 529-534.

Research output: Contribution to journalArticle

Thompson, IM, Ankerst, DP, Chi, C, Goodman, PJ, Tangen, CM, Lucia, MS, Feng, Z, Parnes, HL & Coltman, CA 2006, 'Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial', Journal of the National Cancer Institute, vol. 98, no. 8, pp. 529-534. https://doi.org/10.1093/jnci/djj131
Thompson, Ian M. ; Ankerst, Donna P ; Chi, Chen ; Goodman, Phyllis J. ; Tangen, Catherine M. ; Lucia, M. Scott ; Feng, Ziding ; Parnes, Howard L. ; Coltman, Charles A. / Assessing prostate cancer risk : Results from the Prostate Cancer Prevention Trial. In: Journal of the National Cancer Institute. 2006 ; Vol. 98, No. 8. pp. 529-534.
@article{a42cf3f22b2c4f71b2616648f6982cfe,
title = "Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial",
abstract = "Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. Methods: We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy. Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy. Risk equations were created from the estimated logistic regression models. All statistical tests were two-sided. Results: A total of 1211 (21.9{\%}) men were diagnosed with prostate cancer by prostate biopsy. Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE result, whereas a previous negative prostate biopsy was associated with reduced risk. Neither age at biopsy nor PSA velocity contributed independent prognostic information. Higher PSA level, abnormal DRE result, older age at biopsy, and African American race were predictive for high-grade disease (Gleason score ≥7) whereas a previous negative prostate biopsy reduced this risk. Conclusions: This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.",
author = "Thompson, {Ian M.} and Ankerst, {Donna P} and Chen Chi and Goodman, {Phyllis J.} and Tangen, {Catherine M.} and Lucia, {M. Scott} and Ziding Feng and Parnes, {Howard L.} and Coltman, {Charles A.}",
year = "2006",
month = "4",
day = "19",
doi = "10.1093/jnci/djj131",
language = "English (US)",
volume = "98",
pages = "529--534",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Assessing prostate cancer risk

T2 - Results from the Prostate Cancer Prevention Trial

AU - Thompson, Ian M.

AU - Ankerst, Donna P

AU - Chi, Chen

AU - Goodman, Phyllis J.

AU - Tangen, Catherine M.

AU - Lucia, M. Scott

AU - Feng, Ziding

AU - Parnes, Howard L.

AU - Coltman, Charles A.

PY - 2006/4/19

Y1 - 2006/4/19

N2 - Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. Methods: We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy. Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy. Risk equations were created from the estimated logistic regression models. All statistical tests were two-sided. Results: A total of 1211 (21.9%) men were diagnosed with prostate cancer by prostate biopsy. Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE result, whereas a previous negative prostate biopsy was associated with reduced risk. Neither age at biopsy nor PSA velocity contributed independent prognostic information. Higher PSA level, abnormal DRE result, older age at biopsy, and African American race were predictive for high-grade disease (Gleason score ≥7) whereas a previous negative prostate biopsy reduced this risk. Conclusions: This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.

AB - Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. Methods: We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy. Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy. Risk equations were created from the estimated logistic regression models. All statistical tests were two-sided. Results: A total of 1211 (21.9%) men were diagnosed with prostate cancer by prostate biopsy. Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE result, whereas a previous negative prostate biopsy was associated with reduced risk. Neither age at biopsy nor PSA velocity contributed independent prognostic information. Higher PSA level, abnormal DRE result, older age at biopsy, and African American race were predictive for high-grade disease (Gleason score ≥7) whereas a previous negative prostate biopsy reduced this risk. Conclusions: This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.

UR - http://www.scopus.com/inward/record.url?scp=33646459214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646459214&partnerID=8YFLogxK

U2 - 10.1093/jnci/djj131

DO - 10.1093/jnci/djj131

M3 - Article

VL - 98

SP - 529

EP - 534

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8

ER -